NCT02340195View on ClinicalTrials.gov

Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2015

Conditions
Alzheimer Disease
Interventions
DRUG

Idalopirdine (Lu AE58054) 60 mg

encapsulated film-coated tablets for oral use once daily for 10 days

Trial Locations (1)

Unknown

DE801, München

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02340195 - Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function | Biotech Hunter | Biotech Hunter